Back to Search
PHILIP RASKIN, MD
MD
Endocrinology, Diabetes & Metabolism Physician
NPI: 1528024098IndividualAccepts Medicare
Specialties, Licenses & Credentials
Endocrinology, Diabetes & Metabolism PhysicianPrimary
Internal Medicine — Endocrinology, Diabetes & Metabolism
Code: 207RE0101X
D7661(TX)
Education
UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE
Class of 1966
Clinical Trials (1)
1
Linked Trials
0
Recruiting
1
With Results
Research & Publications (20)
Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control.
PMID 19531054·Diabetes Obes Metab·2009
4-observational
Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet.
PMID 19476470·Diabetes Obes Metab·2009
4-observational
Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes.
PMID 19565569·Diabetes Metab Res Rev·2009
4-observational
Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
PMID 17941873·Diabetes Obes Metab·2009
4-observational
Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
PMID 18494804·Diabetes Obes Metab·2008
6-review
Basal insulin or premix analogue therapy in type 2 diabetes patients.
PMID 17223044·Eur J Intern Med·2007
8-other
Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
PMID 15677776·Diabetes Care·2005
3-trial
Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
PMID 15049934·Diabet Med·2004
3-trial
Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects.
PMID 15365138·Neurology·2004
3-trial
Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study.
PMID 12941725·Diabetes Care·2003
3-trial
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
PMID 12832314·Diabetes Care·2003
3-trial
A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
PMID 11423507·Diabetes Care·2001
3-trial
Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
PMID 10895850·Diabetes Care·2000
3-trial
Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes.
PMID 10834413·Diabetes Care·2000
3-trial
A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.
PMID 11092290·Diabetes Care·2000
3-trial
Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.
PMID 10768088·Diabetologia·2000
3-trial
Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
PMID 19515182·Diabetes Obes Metab·2009
4-observational
Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better?
PMID 19592630·Diabetes Care·2009
2-rct
Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review.
PMID 19436644·Vasc Health Risk Manag·2009
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5323 HARRY HINES BLVD
DALLAS, TX 75390 - Phone
- (214) 645-2868
Quick Facts
- NPI
- 1528024098
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 60
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile